Hair loss with levetiracetam in five patients with epilepsy  by Zou, Xuemei et al.
Seizure 23 (2014) 158–160Short communication
Hair loss with levetiracetam in ﬁve patients with epilepsy
Xuemei Zou, Zhen Hong, Dong Zhou *
Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China
A R T I C L E I N F O
Article history:
Received 24 September 2013
Received in revised form 8 November 2013
Accepted 8 November 2013
Keywords:
Epilepsy
Levetiracetam
Hair loss
A B S T R A C T
Purpose: To report cases of hair loss with levetiracetam (LEV) in epilepsy patient and summarise their
demographic and clinical features.
Method: All patients reported attended the epilepsy outpatient clinic of the West China Hospital,
Sichuan University. Demographic and clinical information was obtained from medical records and by
interview. All the patients were under regular follow up.
Results: Five epilepsy patients (4 females and 1 male) are reported. All developed hair loss within two
months of starting LEV treatment. Three had idiopathic epilepsy, two symptomatic epilepsy. Three
patients received LEV monotherapy, two combination treatment. None decided to switch away from LEV
to another drug after developing hair loss, although the dose of LEV was reduced in one patient.
Conclusion: Hair loss may be a rare side effect of LEV treatment in patients with epilepsy. LEV-related
hair loss appears reversible if the dose is reduced or treatment is stopped.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Levetiracetam (LEV) is a second-generation anticonvulsant
approved by the Federal Drug Administration in 1999 for the
treatment of epilepsy. It has been reported that LEV has a low
incidence of both adverse effects and interactions with other
antiepileptic drugs.1 Well-known adverse effects of LEV include
somnolence, dizziness, and behavioural abnormalities. In the
treatment of patients with antiepileptic drugs (AEDs), hair loss or
alopecia had commonly been reported in association with
valproate (VPA),2 occasionally with carbamazepine (CBZ)3 and
lamotrigine (LTG),4 and only rarely with LEV5; to our knowledge,
hair loss or alopecia has not been previously reported in Asians
patients. Here, we present ﬁve patients who developed hair loss
after starting LEV therapy and summarise their demographic and
clinical features.
2. Case reports
All patients attended the epilepsy outpatient clinic of the West
China Hospital, Sichuan University. Demographic and clinical
information (Table 1) was obtained from medical records and by
interview.* Corresponding author at: Department of Neurology, West China Hospital,
Sichuan University, No. 37 Guoxue Road, Chengdu, Sichuan 610041, People’s
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A 24-year-old woman was diagnosed with generalised epilepsy
at the age of 21. Her habitual seizures were generalised tonic–
clonic seizures (GTCSs). Cranial MRI was normal and routine
electroencephalography (EEG) showed generalised epileptiform
activity. After the third seizure, the patient started LEV (750 mg/
day) treatment. Two months after starting LEV therapy, the patient
developed appreciable diffuse hair loss, and she was referred to a
dermatologist at our hospital, who then excluded the most
common causes of hair loss, including dermatological problems,
thyroid disease, nutritional deﬁciency and autoimmune distur-
bances such as systemic lupus erythematosus. The patient was not
pregnant and did not receive any other medications than LEV at the
time. Although the patient was told that the hair loss may have
been caused by LEV intake, she was so worried about a recurrence
of her seizures that she decided to continue LEV (750 mg/day). In
the following year, her seizures were controlled well but the hair
loss continued. The dose of LEV was gradually reduced and stopped
over six months, by which time her hair loss demonstrated
improvement and had almost recovered.
2.2. Case 2
A 26-year-old woman was diagnosed with generalised epilepsy
at the age of 24. Her habitual seizures were GTCSs. Cranial MRI was
normal and routine EEG showed generalised epileptiform activity.
After more than one year of TPM (100 mg/day) treatment, the
patient continued to experience regular seizures. LEV (500 mg/day)vier Ltd. All rights reserved.
Table 1
Demographic and clinical characteristics of the ﬁve cases.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (years) 24 26 21 39 31
Gender Female Female Male Female Female
Onset age (years) 21 24 12 6 29
Aetiology of epilepsy Idiopathic Idiopathic Symptomatic Symptomatic Idiopathic
Seizure type GTCSs GTCSs CPS, GTCSs CPS, GTCSs GTCSs
Frequency of seizures (before LEV intake) Weekly Monthly Weekly Weekly Monthly
Epilepsy duration (years) 3 2 9 33 2
MRI Normal Normal Abnormal Abnormal Normal
EEG Abnormal Abnormal Abnormal Abnormal Abnormal
Number of AEDs 1 2 1 3 1
Drugs taken LEV TPM, LEV LEV VPA, OXC, LEV LEV
Dose of LEV (mg/day) 750 1000 1000 1000 500
Time to notice hair loss (weeks) 8 6 8 6 3
Type of hair loss Diffuse Diffuse Diffuse Diffuse Diffuse
Drugs adjusted No Yes No No No
Outcome
Seizure control Well Lower frequency Well Lower frequency Well
Hair loss Remitted Improved Improved Improved Remitted
Abbreviations: GTCSs, generalised tonic–clonic seizures; CPS, complex partial seizure; AEDs, antiepileptic drugs; VPA, valproate; OXC, oxcarbazepine; LEV, levetiracetam.
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another seizure. One month after starting LEV (1000 mg/day), the
patient noticed increasing hair loss. She was referred to a
dermatologist, who excluded the most common causes of hair loss.
The hair loss was considered to be secondary to LEV. Due to the good
treatment response, LEV was not stopped but was decreased to
750 mg/day. At a four-month follow-up, seizures had not recurred,
but her hair loss had improved, although it had not remitted
completely.
2.3. Case 3
A 21-year-old man was diagnosed with partial epilepsy and had
suffered from complex partial seizures (CPSs) and secondarily
GTCSs since the age of 12. Cranial MRI showed changes in the right
occipital lobe most likely to have been caused by a dysplasia, and
routine EEG showed focal epileptiform activity mainly in the right
occipital zone. The patient had taken VPA (1500 mg/day) since the
age of 14. This treatment had been stopped approximately two
years previously, at which time the LEV (1000 mg/day) treatment
had been started. Two months after starting LEV treatment, the
patient noticed appreciable hair loss. As the most common causes
of hair loss had been excluded by a dermatologist, the hair loss was
considered most likely to be associated with the LEV treatment.
However, the patient decided to continue the LEV (1000 mg/day)
treatment, as it seemed effective for his seizures. In the following
months, the hair loss continued, but his seizures were well-
controlled. After the patient had been seizure free for one year, the
dose of LEV was reduced to 750 mg/day, and at three-month
follow-up, his hair loss demonstrated improvement.
2.4. Case 4
A 39-year-old woman was diagnosed with partial epilepsy at the
age of 6. Her habitual seizures were CPSs and secondarily GTCSs.
Cranial MRI showed changes in the left temporal lobe most likely to
have been caused by a dysplasia, and routine EEG showed focal
epileptiform activity mainly in the left temporal and frontal zone.
The patient had been treated with VPA (1000 mg/day) in combina-
tion with clonazepam (2 mg/day) since the age of 26, and
oxcarbazepine (600 mg/day) was added and clonazepam was
stopped two year prior to her presentation. However, she continued
to experience frequent seizures and LEV (1000 mg/day) was started
as add-on therapy. At a two-month follow-up, the patient reportedno seizures but had developed diffuse hair loss approximately six
weeks after starting LEV. The hair loss was considered due to LEV, as
the most common causes of hair loss had been excluded by a
dermatologist. However, as her epilepsy had proven refractory to
other treatments and appeared to be responding to LEV (1000 mg/
day), the patient agreed to continue this treatment. At a three-month
follow-up, although the hair loss continued, the seizures were
controlled well, and the patient continued treatment despite
continuing hair loss.
2.5. Case 5
A 31-year-old woman was diagnosed with generalised epilepsy
at the age of 29 when she had two GTCSs at night during sleep in a
one-month period. Cranial MRI was normal and routine EEG
showed generalised epileptiform activity. The patient was given
LEV (500 mg/day) after the second seizure. At two-month follow-
up, the patient complained that she noticed increasing hair loss
approximately three weeks after LEV was initiated. She went to see
a dermatologist, who excluded the most common causes of hair
loss, and the association of the hair loss with the administration of
LEV was noted. However, as the patient worried more about the
risk of seizure recurrence and she did not ﬁnd the hair loss
intolerable, she agreed to continue to take the treatment. In the
following year, the hair loss continued, but she did not become
bald, and her seizures were well-controlled. Thereafter, the dose of
LEV was gradually tapered and the drug was stopped altogether six
months later. Her hair loss gradually stopped and her hair
recovered completely.
3. Discussion
As there was a plausible temporal relationship between hair
loss in these ﬁve patients and the administration of LEV, and as the
most common causes of hair loss had been excluded, we suggest
that our patients’ hair loss was induced by LEV. However, LEV-
induced hair loss appears reversible, as is observed in our patients
that hair loss was improved or settled after the LEV treatment was
stopped completely in two cases and reduced in another two.
Drugs can affect hair follicles primarily through two mecha-
nisms: (i) by inducing an abrupt cessation of mitotic activity in
rapidly dividing hair matrix cells, namely anagen efﬂuvium, which
is a prominent adverse effect of antineoplastic agents, or (ii) by
inducing the premature rest of follicles, namely telogen efﬂuvium,
X. Zou et al. / Seizure 23 (2014) 158–160160which may be a consequence of a large number of drugs
including anticoagulants, interferons, antihyperlipidaemic
drugs,6 and AEDs.7,8 Accordingly, the hair loss in our report
could be due to telogen efﬂuvium. Although the mechanism by
which AEDs causes hair loss remains unclear, zinc depletion has
been reported to be the likely mechanism through which VPA
causes alopecia,2,9 which is similar to the LEV-induced hair loss.5
This is supported by the ﬁnding that LEV enhances GABAergic
transmission by contrast to zinc antagonism at GABAA and
glycine receptors,10 and phenytoin, the only other AED prevent-
ing zinc antagonism that is similar to LEV, has also been
associated with hair loss.10 However, two of the ﬁve patients in
our report did not developed hair loss over a long period of VPA
treatment, indicating that the hair loss induced by LEV and VPA
does not necessarily share a common mechanism; this needs to
be further investigated.
In summary, patients and clinicians should be aware of hair loss
as a possible rare side effect of LEV treatment. As the LEV-induced
hair loss improved after drug tapering or withdrawal, patients and
clinicians should consider whether to reduce or stop LEV if they
experience hair loss. If severe hair loss occurs, the dose should be
adjusted or a switch to another therapy is warranted; in this way,
patients’ compliance is likely to be much better – a phenomenon
which is likely to contribute to the effectiveness of antiepileptic
medication.Conﬂict of interest statement
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